ABG Sundal Collier acted as Sole Global Coordinator in the SEK 91 million share issue in Isofol Medical

On 4 July 2025, Isofol Medical announced the successful completion of the fully subscribed rights issue of units of SEK 91 million including an overallotment issue of SEK 5 million. The proceeds raised secures funding for the expanded Phase II study for the company’s drug candidate, arfolitixorin.
In addition to the initially raised SEK 91 million, two series of warrants were issued as part of the rights issue of units, which may yield additional gross proceeds totalling SEK 112 million if subscribed for in full during March 2026 and November 2026.